Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females Group B Streptococcus (GBS) is the leading cause of ...

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for ...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...

Group B Strep (GBS) is just one of the many bacterial communities that colonize a healthy adult. GBS bacteria live harmlessly in approximately 25 percent of healthy women. However, when the bacteria ...

The number of diagnostic tests used to evaluate biological material has exploded over the last decades. These tests help identify disease, determine treatment and show whether or not a condition is ...

Nexsen is commercialising novel point-of-care diagnostic tech developed by RMIT University The company’s first target is group B streptococcus (GBS) bacteria, a potentially dangerous disease affecting ...